In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% ...

AstraZeneca’s experimental pill has shown promise in reducing “bad” cholesterol, raising expectations for more convenient alternatives in treatment options. AstraZenca is testing a once-daily PCSK9 ...

Over the years, there have been significant changes to the dyslipidemia medication management guidelines, alongside ...

New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers ...

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...

Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...

Cholesterol synthesis and gallstone formation are promoted by trimethylamine-N-oxide (TMAO), a derivative of trimethylamine, ...

Oral PCSK9 inhibitor, AZD0780, demonstrated a significant 50.7% reduction in LDL cholesterol levels in the Phase IIb PURSUIT ...

It acts as a small molecule inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), which binds to a novel pocket ...

Other medications, such as sequestrants, PCSK9 inhibitors, cholesterol absorption inhibitors, and ACL inhibitors (or a combination of these), are effective alternatives. Your best treatment option ...